Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.

Date publication

mai 2026

Journal

NEJM evidence

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DAGUINDAU Etienne

Tous les auteurs :
Kaya DE, Cook R, Iacobelli S, Napolitani G, Gerlevik S, Seymen N, Sicre de Fontbrune F, Griffin M, Frieri C, Halkes CJM, Recher C, Barraco F, Forcade E, Méar JB, Laurino M, Drexler B, Daguindau E, van Os M, Terwel S, Dufour C, Karimi MM, Kulasekararaj AG, Peffault De Latour R, Risitano AM, Mufti G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42047558

Résumé

A Phase 3 randomized trial compared immunosuppressive therapy with or without eltrombopag in untreated patients with aplastic anemia (AA) and showed that addition of eltrombopag increased the rate, rapidity, and durability of hematological response, without increasing transformation to myeloid malignancies. We sought to systematically investigate clonal hematopoiesis (CH) dynamics from patient samples from this trial.

Mots clés

Humans, Anemia, Aplastic, drug therapy, Hydrazines, therapeutic use, Pyrazoles, therapeutic use, Benzoates, therapeutic use, Female, Male, Adult, Middle Aged, Mutation, Immunosuppressive Agents, therapeutic use, Clonal Hematopoiesis, drug effects, Aged, Young Adult, Hematopoiesis, drug effects, Adolescent, Immunosuppression Therapy

Référence

NEJM Evid. 2026 05;5(5):EVIDoa2500174